Ionis Q2 revenue doubles to $452M; raises FY 2025 guidance, TRYNGOLZA sales $19M

IONIS PHARMACEUTICALS INC

2025-Q2 EPS reported -$0.15 revenue$583,660,000

Q2 total revenue $452M (up from $225M); GAAP income from ops $140M vs loss $66M year ago.
TRYNGOLZA net product sales $19M in Q2, first half $26M; SPINRAZA royalties $54M, WAINUA royalties $10M.
FY 2025 guidance raised: total revenue $825-850M (from $725-750M); TRYNGOLZA sales guided at $75-80M.
Donidalorsen expected approval Aug 21, 2025; Phase 3 olezarsen sHTG data due September.
Received $280M upfront from sapablursen license; cash & investments $2.3B; CFO raised non-GAAP op loss guidance to $300-325M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.